89Zr-RO5323441 PET imaging in patients with recurrent glioblastoma treated with bevacizumab

Trial Profile

89Zr-RO5323441 PET imaging in patients with recurrent glioblastoma treated with bevacizumab

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs THR 317 (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Mar 2014 Trial status changed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 09 Dec 2013 Planned end date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 21 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01622764).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top